arrow
S

Shukaib Arslan

ut southwestern medical center
H指数:16
被引数:786

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide

CHIME:一种新型HLA表位模型与含移植后环磷酰胺的半相合造血细胞移植的非复发死亡率相关

2026-07-040
OA
A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Ib期研究:重组人白介素-22受体激动剂efmarodocokin alfa联合标准治疗方案在异基因造血干细胞移植患者中的应用

2026-06-010
OAAI
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation

无残疾生存:老年异基因造血细胞移植的一种新型疾病终点

2026-03-280
PRE
Impact of Itacitinib Exposure on Immune Reconstitution and Cytokine Profile Following HLA-Matched Allogeneic Hematopoietic Cell Transplantation (HCT) with Tacrolimus, Sirolimus, and Itacitinib GVHD Prophylaxis
2026-02-030
PRE
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden

细胞减灭术对高肿瘤负荷复发或难治性B-ALL患者博纳吐莫单抗疗效的影响

2025-09-090
PRE
Outcomes After Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment

基于美法仑的减低强度异基因造血细胞移植在肾功能不全患者中的结局

2025-07-010
PRE
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission

成人B细胞前体急性淋巴细胞白血病患者在可测量微小残留病阴性缓解状态下,将blinatumomab巩固治疗整合到CALGB 10403方案中。

2025-06-100
PRE
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect

基于美法仑的预处理联合移植后环磷酰胺用于外周血干细胞移植:供者效应

2025-02-270
OA
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
2025-02-200
OAAI
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
2024-10-011
PRE
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation
2024-10-010
PRE
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
2024-05-281
PRE
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
2024-02-015
PRE
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis
2023-08-014
OAAI
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab
2023-05-015
OAAI